Introduction
============

Colorectal cancer (CRC) ranks among the second leading cause of cancer-related mortality in the United States and remains the fourth most common cause of cancer deaths worldwide[@B1]. The burden of CRC in China is also a severe public health issue. In 2015, there were 191 thousand CRC deaths cases according to the data from the National Central Cancer Registry of China [@B2]. Although the improvements in early screening such as guaiac fecal occult blood tests (gFOBT), fecal immunochemical test (FIT) and fibercoloscope ameliorate therapeutics management of patients with early stage of this disease, the five-year overall survival rates of individuals with advanced and metastatic stages remain bleak due to the lack of useful and clinically- actionable tumor biomarkers for the prognosis monitoring [@B3]-[@B5]. To date, only serum carcinoembryonic antigen (CEA) measurement is recommend for the over-all post-surgical surveillance of early recurrence in CRC. However, there is no universal standard for the frequency of CEA testing and its high false-positive rate limits its monitoring value. These data highlight the critical and imperative need for identification of effective and sensitive biomarkers for assisting surgeons in developing a therapeutics.

Recent researches emphasized a integrative strategy for molecular subtyping[@B6], but only few tissue biomarkers such as microsatellite instability (MSI) status, CpG island methylator phenotype (CIMP) status, *RAS* mutation, and *BRAF* mutation are applied in clinical-outcome judgement of CRC. Our previous studies have demonstrated that a tumor- suppressive miRNA, miR-150, regulates the tumorigenesis and progression of CRC by post-transcriptionally reducing the expression level of nuclear proto- oncogene, v-myb avian myeloblastosis viral oncogene homolog (c-Myb) in cultured cells and animal models[@B7],[@B8]. As one of the important transcription factors, c-Myb is frequently elevated in a number of carcinomas including acute myelogenous leukemia [@B9],[@B10], salivary adenoid cystic carcinoma[@B11], breast cancer[@B12], and CRC[@B9]. This gene participates in a wide variety of biological life processes including cell proliferation, cell cycle progression, and apoptosis, indicating that the malignancy maintenance of CRC cells is c-Myb dependent[@B13]-[@B15]. Moreover, recent studies discovered the mediation of chronic inflammatory reaction by c-Myb in the gut[@B13]-[@B15]. These findings help us understand why anti- inflammatory therapy is useful in the CRC treatment. Meanwhile, it also reminds us to determine the prognostic value of c-Myb and Inflammatory markers in the post-surgical surveillance of CRC.

As one of the downstream effectors of c-Myb, prostaglandin-endoperoxide synthase 2 (COX-2), is a consistent hallmark feature of gut inflammation and CRC [@B19]. Overexpression of COX-2 has been confirmed to play an important role in epithelial- mesenchymal transition (EMT) and lymph node metastasis[@B20]. However, the clinicopathological relevance of upregulated expression levels of c-Myb in combination with COX-2, in determining the prognosis of CRC patients has not yet been studied. The aim of present study was to determine the expression levels of c-Myb and COX-2 in sporadic CRC, and decipher their prognostic usefulness in this malignancy.

Materials and Methods
=====================

Patient specimens and clinicopathological data collection
---------------------------------------------------------

Matched normal and cancerous colorectal tissues from sporadic CRC patients were obtained from 202 patients (Han Chinese) who received colorectal surgery at the Sixth People\'s Hospital affiliated with Shanghai Jiao Tong University, Shanghai, China, between January 2004 and October 2007. The study was approved by the committee from the Sixth People\'s Hospital affiliated with Shanghai Jiao Tong University. Written informed consent was obtained from the patients, in accordance with the institutional guidelines. The methods were performed in accordance with the approved guidelines. We excluded cases that were diagnosed as familial adenomatous polyposis or with colitis-associated CRC. The endpoints of interest was overall survival. The deadline of follow-up was 1, April 2011 for all CRC cases. Survivors among the cases at last contact were considered as censored for following overall survival analysis. All the patients\' clinicopathological data including age, gender, tumor location, differentiation, tumor size, depth of invasion, lymph node involvement, distant metastatic spread, tumor node metastasis (TNM) stage, 5-fluorouracil (Fu)-based chemotherapy, KI-67 expression, P53 status, and CEA status were obtained from the electronic medical records of the Sixth People\'s Hospital affiliated with Shanghai Jiao Tong University. The summary of clinicopathological data was demonstrated in **table [1](#T1){ref-type="table"}**.

Tissue microarray construction
------------------------------

Formalin-fixed and paraffin-embedded tumor blocks were collected from the archives of the pathological departments at the Sixth People\'s Hospital affiliated with Shanghai Jiao Tong University. After marked on the hematoxylin and eosin slide, the most representative tumor areas of the paraffin blocks were chosen and 2.0-mm dimension tissue cores were arranged in tissue microarray (TMA) blocks. Then, 4.0 μm TMA sections were cut for immunohistochemistry (IHC) analysis.

Immunohistochemistry and staining evaluation
--------------------------------------------

The sections were dried for 2 h at the 65 °C hot air oven, de-waxed by dimethylbenzene and rehydrated in gradient alcohol. Antigen was retrieved in citric acid buffer(PH 6.0) with a pressure antigen retrieval procedure for 5 min. After washing the slides by PBS buffer(PH 7.4), endogenous peroxidase activity was interdicted by incubating the sections for 10 min in endogenous peroxidase blocking solution at room temperature. Non-specific background was blocking by incubating with normal nonimmune goat serum at room temperature for 30 min. The sections were then incubated with following primary antibodies: anti-c-Myb (Rabbit polyclonal, 1:400, Abcam, Cambridge, United Kingdom, ab117635) and anti-COX-2 (Rabbit polyclonal, 1:200, Abcam, Cambridge, United Kingdom, ab15191). The slices incubated with PBS buffer (PH7.4) only were used as negative control. After washing with the PBS buffer (PH7.4), the tissue sections were detected and visualized with the Polink-1 HRP DAB detection system (ZSGB-BIO, Beijing, China). Then the reaction was stopped under running water and the sections were counterstained with Mayer\'s hematoxylin, dehydrated with gradient alcohol, mounted with neutral balsam. The immunoreactivity of each slice was examined by three independent investigators and photographed under the light microscope (Leica DM2000, Germany) with digital camera at high magnification (Leica DFC450C, Germany). The staining immunoreactivity was scored ranged from 0% to 100% (5% as intervals) by calculating the proportion of positive cancerous cells over all areas and the scorers were blinded for each other\' score. A cutoff point of each marker was chosen by using median value to dichotomize cases. Scoring above or below the cutoff point was classified as "elevated" or "decreased", respectively.

Western blotting analysis
-------------------------

Total protein were obtained from three pairs of matched normal and cancerous CRC frozen tissues using RIPA Lysis Buffer (Beyotime, Shanghai, China) according to the specification. Total protein was quantified using a BCA kit (TIANGEN, Beijing, China). SDS-PAGE was performed for 0.5 h at 80 V and then at 120 V for 1.5 h. After electrophoresis, the separated proteins were transferred from the gel to the PVDF membranes (Millipore, Bedford, USA) at 250 mA for 2h at 4°C. Then the PVDF was blocked with skim milk in tris-buffered saline tween (TBST) 1 h at room temperature. Following blocking, the membranes was incubated overnight at 4°C with the primary antibody: anti-c-Myb (Rabbit polyclonal, 1:500, Abcam, Cambridge, United Kingdom, ab117635); anti-COX-2 (Rabbit monoclonal, 1:500, Abcam, Cambridge, United Kingdom, ab62331); anti-beta Actin (Mouse monoclonal, 1:5000, SIGMA, California, USA, A5441). After washing with TBST three times (5 min per wash), the PVDF was incubated with the corresponding secondary antibody (anti-rabbit, 1:5000, LICOR, Nebraska, USA, 926-32223; anti-mouse, 1:5000, LICOR, Nebraska, USA, 926-68072) 1 h at room temperature and analyzed with the Odyssey 3.0 system.

Statistical analysis
--------------------

All statistical analyses were performed by using the IBM SPSS Statistics 20.0 software (IBM, lnc., Chicago, Illinois, USA) and GraphPad Prism 6 software (GraphPad software, lnc., San Diego, California, USA). For comparison of expression of each marker between the CRC tissues and the matched adjacent normal tissues, a paired Student\'s t test was conducted. The proportion values of positively stained cells were transformed using the arcsine-square-root transformation to normalize the data[@B21]. The relationships between c-Myb and COX-2 expression was analyzed using linear or non-linear regression, if appropriate. The associations between the clinicopathological data and the staining of c-Myb and COX-2 were performed using Pearson\'s Chi-square. The impacts of clinical variables and the staining of c-Myb and COX-2 were estimated by using univariate and multivariate Cox proportional hazards regression model. All tests were double tail and the p values below 0.05 were considered significant.

Results
=======

Detection of c-Myb and COX-2 expression in CRC tissues and paired adjacent mucosa
---------------------------------------------------------------------------------

Two hundred and two cases with matched normal and neoplastic tissues from CRC patients were included in our present study. Representative IHC staining of c-Myb and COX-2 for CRC tissues and paired adjacent mucosa are represented in **Figure [1](#F1){ref-type="fig"}.** Immunoreactivity for c-Myb was detected primarily in the nuclei, while COX-2 was expressed primarily in the cytoplasm. The median staining score of c-Myb was 85% in the CRC tissues and 30% in the matched adjacent normal tissues. Meanwhile, the median staining score of COX-2 was 60% in the cancerous tissues and 20% in the matched noncancerous tissues. In agreement with the reported studies[@B9],[@B22],[@B23], the expression levels of both c-Myb (p \< 0.001) and COX-2 (p \< 0.001) were higher in the CRC tissues in comparison with the adjacent normal tissues (**Figure [2](#F2){ref-type="fig"}A & B**).

Furthermore, linear regression model was examined to explore the association between c-Myb and COX-2 expression. A statistically significant correlation was found between the proportional immunostaining level of c-Myb and the expression of COX-2 (r = 0.391, p \< 0.001; **Figure [2](#F2){ref-type="fig"}C**). We further validated the result by Western blot. Compared with noncancerous tissues, the protein expression of c-Myb was found to be upregulated in the CRC tissues, accompanied by high expression of COX-2 (**Figure [2](#F2){ref-type="fig"}D**).

The associations of c-Myb and COX-2 expression with clinicopathological variables
---------------------------------------------------------------------------------

To explore the relationship of c-Myb and COX-2 expression with clinicopathological variables, the median value of each marker was chosen as the cutoff point to dichotomize the staining scores. With this criterion, 116 cases were classified as high-expression and 86 cases as low-expression for c-Myb. Likewise, 102 cases were classified as high-expression and 100 cases as low-expression for COX-2.

As demonstrated in **Table [1](#T1){ref-type="table"}**, elevated c-Myb expression was significantly associated with more advanced tumor invasion (p = 0.020) and higher TNM stage (p = 0.019). Although the elevated c-Myb expression was slightly associated with tumor differentiation (p = 0.067) and lymph node involvement (p = 0.062), the results didn\'t reach statistical significance. Elevated COX-2 expression was also significantly correlated with more advanced tumor invasion (p = 0.003) and tumor location (p = 0.030). Among variables including age, gender, tumor differentiation, tumor size, lymph node involvement, distant metastatic spread, TNM stage, 5-Fu-based chemotherapy, KI-67 expression, P53 status and CEA status, there was no association between these variables and the COX-2 expression.

Expression of c-Myb and COX-2 correlated with poor overall survival in colorectal carcinoma
-------------------------------------------------------------------------------------------

Univariate associations of the expression of each protein with overall survival were listed in **Table [2](#T2){ref-type="table"}**. Poorer tumor differentiation (Hazard ratio (HR), 2.348; 95% confidence interval (95% CI), 1.272 - 4.333; p = 0.006), more depth of invasion (HR, 4.324; 95% CI, 1.365 - 13.698; p = 0.013), positive lymph node involvement (HR, 4.000; 95% CI, 2.545 - 6.286; p \< 0.001), positive distant metastatic spread (HR, 3.407; 95% CI, 1.752 - 6.623; p \< 0.001), higher TNM stage (HR, 2.637; 95% CI, 1.975 - 3.520; p \< 0.001), and positive CEA status (HR, 1.583; 95% CI, 1.019 - 2.458; p = 0.041) demonstrated shorter overall survival of CRC. Cases with c-Myb overexpression, as determined by IHC, had a 2.693-fold (95% CI, 1.640 - 4.421; p \< 0.001) more risk for death (**Figure [3](#F3){ref-type="fig"}A**). Meanwhile, cases with COX-2 overexpression had a 2.334-fold (95% CI, 1.485 - 3.669; p \< 0.001) poorer overall survival (**Figure [3](#F3){ref-type="fig"}D**).

Multivariate Cox proportional hazards regression analysis was performed using all 202 cases with complete clinical data for variables that were significant on univariate model (**Table [2](#T2){ref-type="table"}**). After multivariable adjustment by considering the clinicopathological variables including tumor differentiation, depth of invasion, lymph node involvement, distant metastatic spread, TNM stage, and CEA status, only the lymph node involvement (HR, 3.535; 95% CI, 1.127 - 11.084; p = 0.030), distant metastatic spread (HR, 2.247; 95% CI, 1.014 - 4.978; p = 0.046), and expression of c-Myb and COX-2 remained independently significant. Tumor tissues with elevated c-Myb expression had a 1.841-fold (95% CI, 1.082 - 3.133; p = 0.024) more risk for death. Tumor tissues with COX-2 overexpression had a 1.672-fold (95% CI, 1.022 - 2.736; p \< 0.041) poorer overall survival.

To further investigate the influence of c-Myb and COX-2 expression on patients with adjuvant chemotherapy, we conducted subgroup analysis in patients with or without 5-Fu-based chemotherapy. Elevated expression of c-Myb or COX-2 had a worse response to 5-Fu-based chemotherapy (p \< 0.001 and p = 0.001, respectively; **Figure [3](#F3){ref-type="fig"}C, 3F**) in comparison with patients without chemotherapy (p = 0.024 and p = 0.039, respectively; **Figure [3](#F3){ref-type="fig"}B, 3E**).

Combination of c-Myb and COX-2 in predicting prognosis of CRC
-------------------------------------------------------------

To confirm that the combination of c-Myb and COX-2 may help predict prognosis of CRC patients, we constructed three subgroups based on the expression levels of both genes: subgroup 1, low c-Myb and low COX-2; subgroup 2, (low c-Myb and high COX-2) or (high c-Myb and low COX-2); subgroup 3, high c-Myb and high COX-2. As expected, overexpression of both genes predicted worse overall survival (p \< 0.001; **Figure [4](#F4){ref-type="fig"}A**). When stratified by 5-Fu-based chemotherapy, the promising prognostic model by combination of c-Myb and COX-2 were yet again confirmed, suggesting that the two markers may help to predict and select the effect of chemotherapy on survival time in patients with CRC (**Figure [4](#F4){ref-type="fig"}B, 4C**).

5-Fu-based adjuvant chemotherapy is established routine therapy for CRC patients with stage Ⅱ and stage Ⅲ disease, especially for those with poor prognostic features. When further stratified by TNM stage, the co-overexpression of both genes was still of value for prognostic evaluation. In detail, overexpression of c-Myb and COX-2 was significantly associated with shorter overall survival for stage Ⅱ (p = 0.028; **Figure [5](#F5){ref-type="fig"}A, 5B**) and stage Ⅲ (p = 0.003; **Figure [5](#F5){ref-type="fig"}C, 5D**) patients with 5-Fu based chemotherapy.

Discussion
==========

Although our previous study identified the oncogenic role of c-Myb in cellular apoptosis, progression and proliferation in cultured cells and an animal model, its clinical significance remains unclear and requires interrogation[@B7]. In this study, we have firstly developed a prognostic model based on two proteins to enhance and better predict the prognosis of CRC. Our study presented that the proportional immunostaining level of c-Myb was significantly correlated with the expression of COX-2. The expression level of c-Myb in combination with COX-2 can fairly well categorize CRC cases into low- and high-risk phenotypes with difference in overall survival rate. Cases with high c-Myb and COX-2 were involved in worse response to chemotherapy.

The MYB family of the transcription factor genes contain c-Myb, b-Myb and a-Myb[@B24]. All members of the MYB family contain a conserved DNA-binding domain[@B24]. Compelling studies have shown that c-Myb plays a pivotal role of proto-oncogenes in cancers including CRC[@B25]. However, a recent study published by Michal Tichý found a negative association between the expression of c-Myb in CRC tissue and the presence of distant metastases[@B26]. Considering that both pro-invasive and anti- metastatic roles of c-Myb were described, we examined the expression of c-Myb at protein level in 202 CRC tissue samples and verified it at mRNA level using public databases from The Cancer Genome Atlas (TCGA) cohort of patients with colon adenocarcinoma (TCGA COAD). In agreement with the reported studies[@B9],[@B22],[@B27], we found that the expression of c-Myb (p \< 0.001), detected by IHC, was significantly higher in the CRC tissues in comparison with the adjacent normal tissues. Meanwhile, elevated expression of c-Myb was significantly associated with more advanced tumor invasion (p = 0.020), higher TNM stage (p = 0.019) and poorer overall survival (p \< 0.001). Whereas, there were no significant association between the amount of the *c-Myb* mRNA and the poor outcome of patients with CRC according to the TCGA COAD (**Supplementary table [S1](#SM0){ref-type="supplementary-material"}**). These findings supported the fact that the protein level of the *c-Myb*, but not the amount of the gene mRNA, may serve as a good prognostic marker.

As a nuclear transcription factor, c-Myb participates in diverse cellular processes by up-regulation of its downstream transcriptional targets including COX-2[@B28]-[@B30]. COX-2 inhibits apoptosis and promotes cell proliferation in numerous cancers including breast cancer[@B31],[@B32], cervical cancer[@B33], lung cancer[@B34], gastric cancer[@B35], and CRC[@B36]. A myriad of literature has confirmed that long-term therapy with non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, or selective COX-2 inhibitors like celecoxib, are associated with a reduced risk of CRC[@B36]-[@B39]. When it comes to the prognostic value, the COX2 expression by IHC was found to have a significant correlation with tumor stage, despite few studies demonstrated a negative effect[@B40]-[@B42].

Ramsay and his colleagues were the first to demonstrate that human COX-2 promoter contains a high-affinity binding site of c-Myb. Given that both c-Myb and COX-2 drive tumor progression[@B29], we have reason to believe that using c-Myb-COX-2 partner model to predict CRC prognosis may be better than utilizing any of the single indicator. A recent study had found that the combination of c-Myb, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (c-kit), and COX-2 show better clinical significance in predicting prognosis in salivary adenoid cystic carcinoma[@B43]. However, the relationship between c-Myb and COX-2 in CRC hasn\'t been verified in clinic specimens up to now. In this context our findings have important clinical significance and urge us to confirm the prognostic value of c-Myb-COX-2 partner model in CRC. In our study, both univariate and multivariate Cox proportional hazards regression analysis supported that cases with high c-Myb and COX-2 indicated poorer overall survival. When stratified by 5-Fu-based chemotherapy status and TNM stage, the prognostic value by combination of c-Myb and COX-2 were reconfirmed and validated. These findings suggest that the overexpression of both c-Myb and COX-2 is of prognostic screening value in patients with CRC. However, according to the TCGA COAD database, there were no significant association between the mRNA level of both gene and the prognosis of CRC (**Supplementary table [S2](#SM0){ref-type="supplementary-material"}**). The reason for this could be that c-Myb and COX2 promotes the progression of the disease mainly at the posttranscriptional level. Studies based on gain-of-functions/loss-of-functions experiments are required to further explain this phenomenon.

In conclusion, our present study demonstrates that both the c-Myb and COX-2 are two independent prognostic biomarkers and the c-Myb-COX-2 model reinforces the function in prognostic assessment in patients with CRC.
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![**Representative IHC staining of c-Myb and COX-2 for CRC tissues and paired adjacent mucosa. A)** IHC of c-Myb protein in tumorous or adjacent normal tissues. **B**) IHC of COX-2 protein in tumorous or adjacent normal tissues. **C**) Low and high expression level of c-Myb protein in tumorous tissues. **D**) Low and high expression level of COX-2 protein in tumorous tissues. Original magnifications: ×100 or ×200.](jcav10p1601g001){#F1}

![**The positive expression rate of c-Myb and COX-2 in CRC. A)** IHC detection of c-Myb in 202 paired of CRC and noncancerous tissues (paired Student\'s t test; \*\*\*, p \< 0.001); **B**) IHC detection of COX-2 in 202 paired of CRC and noncancerous tissues (paired Student\'s t test; \*\*\*, p \< 0.001). **C**) Correlation of c-Myb expression with COX-2 expression (linear regression; r = 0.391, p \< 0.001). D) Western blot analysis of the protein expression of c-Myb and COX-2 in the CRC tissues, as compared with noncancerous tissues.](jcav10p1601g002){#F2}

![**The influence of c-Myb and COX-2 expression for overall survival in CRC. A**) Relationship of c-Myb expression to overall survival in all 202 patients (log-rank; p \< 0.001). **B**) Relationship of c-Myb expression to overall survival in patients without 5-Fu-based chemotherapy (log-rank; p = 0.024). **C**) Relationship of c-Myb expression to overall survival in patients with 5-Fu-based chemotherapy (log-rank; p \< 0.001). **D**) Relationship of COX-2 expression to overall survival in all 202 patients (log-rank; p \< 0.001). **E)** Relationship of COX-2 expression to overall survival in patients without 5-Fu-based chemotherapy (log-rank; p = 0.039). **F)** Relationship of COX-2 expression to overall survival in patients with 5-Fu-based chemotherapy (log-rank; p = 0.001).](jcav10p1601g003){#F3}

![**Combination of c-Myb and COX-2 in predicting prognosis of CRC. A, B** and **C**) Combination of both up-regulated molecules predicted worse overall survival in all patients (A; log-rank; p \< 0.001 for subgroup 2 and p \< 0.001 for subgroup 3, respectively) or in patients without 5-Fu-based chemotherapy (B; log-rank; p = 0.002 for subgroup 2 and p = 0.004 for subgroup 3, respectively) or in patients with 5-Fu-based chemotherapy (C; log-rank; p \< 0.001 for subgroup 2 and p \< 0.001 for subgroup 3, respectively). Subgroup 1, low c-Myb and low COX-2; subgroup 2, (low c-Myb and high COX-2) or (high c-Myb and low COX-2); subgroup 3, high c-Myb and high COX-2. Subgroup 1 was chosen as control.](jcav10p1601g004){#F4}

![**Combination of c-Myb and COX-2 in predicting prognosis of CRC in stage II and III patients. A** and **B**) Combination of both up-regulated molecules predicted worse overall survival in stage Ⅱ patients without (A; log-rank; p = 0.748 for subgroup 2 and p = 0.193 for subgroup 3, respectively) or with 5-Fu based chemotherapy (B; log-rank; p = 0.412 for subgroup 2 and p = 0.028 for subgroup 3, respectively). **C** and **D**) Combination of both up-regulated molecules predicted worse overall survival in stage Ⅲ patients without (C; log-rank; p = 0.029 for subgroup 2 and p = 0.349 for subgroup 3, respectively) or with 5-Fu based chemotherapy (D; log-rank; p \< 0.001 for subgroup 2 and p \< 0.001 for subgroup 3, respectively). Subgroup 1, low c-Myb and low COX-2; subgroup 2, (low c-Myb and high COX-2) or (high c-Myb and low COX-2); subgroup 3, high c-Myb and high COX-2. Subgroup 1 was chosen as control.](jcav10p1601g005){#F5}

###### 

Clinicopathological variables and the expressions of c-Myb and COX-2 in patients with colorectal cancer

  Characteristics                 Total   Tumor c-Myb expression        Tumor COX-2 expression                  
  ------------------------------- ------- ------------------------ ---- ------------------------ -- ----- ----- -------
  **All cases**                   202     116                      86                               102   100   
  **Age (years)**                                                       0.933                                   0.946
  \< 60                           57      33                       24                               29    28    
  ≥ 60                            145     83                       62                               73    72    
  **Gender**                                                            0.894                                   0.195
  Female                          88      51                       37                               49    39    
  Male                            114     65                       49                               53    61    
  **Tumor location**                                                    0.095                                   0.030
  Right hemicolon                 76      51                       25                               47    29    
  Left hemicolon                  61      32                       29                               29    32    
  Rectum                          65      33                       32                               26    39    
  **Differentiation**                                                   0.067                                   0.150
  Well-moderate                   184     102                      82                               90    94    
  Poor                            18      14                       4                                12    6     
  **Tumor size (cm)**                                                   0.812                                   0.199
  \< 5                            110     64                       46                               51    59    
  ≥ 5                             92      52                       40                               51    41    
  **Depth of invasion**                                                 0.020                                   0.003
  Tis - T2                        23      8                        15                               5     18    
  T3 - T4                         179     108                      71                               97    82    
  **Lymph node involvement**                                            0.062                                   0.292
  N0                              126     66                       60                               60    66    
  N1 - N2                         76      50                       26                               42    34    
  **Distant metastatic spread**                                         0.092                                   0.370
  Absence (M0)                    191     107                      84                               95    96    
  Presence (M1)                   11      9                        2                                7     4     
  **TNM stage**                                                                                                 
  0 - Ⅱ                           122     62                       60   0.019                       56    66    0.107
  Ⅲ - Ⅳ                           80      54                       26                               46    34    
  **5-Fu-based chemotherapy**                                           0.654                                   0.481
  Absence                         100     59                       41                               53    47    
  Presence                        102     57                       45                               49    53    
  **KI-67 expression**                                                  0.409                                   0.153
  \< 50%                          71      38                       33                               31    40    
  ≥ 50%                           131     78                       53                               71    60    
  **P53 status**                                                        0.808                       28    36    0.192
  Negative                        64      36                       28                               74    64    
  Positive                        138     80                       58                                           
  **CEA status**                                                        0.569                                   0.778
  Negative                        101     56                       45                               50    51    
  Positive                        101     60                       41                               52    49    

Abbreviations: TNM, tumor node metastasis

###### 

The effects of clinicopathologic variables on overall survival rate by univariate and multivariate Cox proportional hazard regression analysis

  Variables                   Univariate   Multivariate                                         
  --------------------------- ------------ ---------------- ---------- ------- ---------------- -------
  c-Myb                       2.693        1.640 - 4.421    \< 0.001   1.841   1.082 - 3.133    0.024
  COX-2                       2.334        1.485 - 3.669    \< 0.001   1.672   1.022 - 2.736    0.041
  Age                         1.033        0.643 - 1.661    0.892                               
  Gender                      0.957        0.621 - 1.476    0.843                               
  Tumor location              0.910        0.698 - 1.185    0.482                               
  Differentiation             2.348        1.272 - 4.333    0.006      1.409   0.749 - 2.651    0.288
  Tumor size                  1.192        0.775 - 1.833    0.425                               
  Depth of invasion           4.324        1.365 - 13.698   0.013      1.995   0.612 -6.500     0.252
  Lymph node involvement      4.000        2.545 - 6.286    \< 0.001   3.535   1.127 - 11.084   0.030
  Distant metastatic spread   3.407        1.752 - 6.623    \< 0.001   2.247   1.014 - 4.978    0.046
  TNM stage                   2.637        1.975 - 3.520    \< 0.001   0.945   0.285 - 3.134    0.927
  5-Fu-based chemotherapy     1.038        0.674 - 1.598    0.865                               
  KI-67 expression            1.212        0.762 - 1.928    0.417                               
  TP53 status                 1.318        0.814 - 2.135    0.262                               
  CEA status                  1.583        1.019 - 2.458    0.041      1.258   0.795 - 1.990    0.326

Abbreviations: TNM, tumor node metastasis; HR, hazard ratio; CI, confidence interval.
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